Status:
COMPLETED
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-...
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia (currently unmedicated)
- Subjects at risk for the development of schizophrenia (prodromal symptoms)
- Healthy subjects
- Written informed consent
Exclusion
- Neurological or severe somatic disorders
- Women during pregnancy or lactation
- Occupational exposition to radiation \> 15mSv
- Medication known to interfere with IBZM
- Contraindications for the use of amphetamine challenge
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00166322
Start Date
January 1 2004
End Date
December 1 2007
Last Update
May 7 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Psychiatry
Munich, Germany, D-80336
2
Dept. of Nuclear Medicine
Munich, Germany, D-81377